The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

The companies Treeline Biosciences, Kailera Therapeutics, and Seaport Therapeutics bagged the biggest private biotech ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.

Osteoarthritis of the knee is a common and often painful condition affecting millions worldwide, especially older adults. As weight loss medications like Ozempic continue to gain traction for their ...

LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...

Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.

Current health news highlights the expected high demand for Novo Nordisk's obesity drug in India, the need for personalized approaches in knee replacement surgeries, Gilead's notable financial ...

Peter Bains, Group CEO of Biocon, talks about how the India-based pharmaceutical company is placed ahead of a second Trump ...

Shares in Novo Nordisk which competes with Eli Lilly in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, rose nearly 9%.

He took a position in 2015 as chairman of an organization called Children’s Health Defense, which puts vaccines as its first concern on its website. The organization questions the health, safety and ...

Ozempic (semaglutide) may impact kidney health in certain people, especially those with diabetes. Learn more about what the ...